BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 6635629)

  • 1. [Ovarian cancers--a solution within reach?].
    Haller U; Lütolf UM; Jungi WF
    Schweiz Med Wochenschr; 1983 Sep; 113(36):1300-5. PubMed ID: 6635629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current management of malignant germ cell tumor of the ovary.
    Aziz MF
    Gan To Kagaku Ryoho; 1995 Aug; 22 Suppl 3():262-76. PubMed ID: 7661594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.
    Veras E; Deavers MT; Silva EG; Malpica A
    Am J Surg Pathol; 2007 May; 31(5):774-82. PubMed ID: 17460463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Negative second-look laparatomy in ovarian cancers. Survival analysis and prognostic factors from 64 cases treated at the Gustave Roussy Institute].
    Pautier P; Rey A; Michel G; Castaigne D; Rochard F; Duvillard P; Haie-Meder C; Curcio P; Benedetti-Richard L; Lhommé C
    Bull Cancer; 1997 Feb; 84(2):147-54. PubMed ID: 9180837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gynecological malignancies.
    Schaebler DL; Schilder RJ; Young RC
    Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic results of malignant ovarian tumor].
    Fukazawa I; Masubuchi S; Okajima H; Fukuda K; Hayashi K; Yokosuka K; Miyata R; Masubuchi K
    Gan No Rinsho; 1984 Jun; 30(7):819-26. PubMed ID: 6431145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant mixed mesodermal ovarian tumor treatment and prognosis: a 20-year experience.
    Le T; Krepart GV; Lotocki RJ; Heywood MS
    Gynecol Oncol; 1997 May; 65(2):237-40. PubMed ID: 9159331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
    Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
    Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment.
    Del Campo JM; Felip E; Rubio D; Vidal R; Bermejo B; Colomer R; Zanon V
    Gynecol Oncol; 1994 Apr; 53(1):27-32. PubMed ID: 8175018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T; Adolph A; Krepart GV; Lotocki R; Heywood MS
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of early ovarian cancer: germ cell and sex cord-stromal tumors.
    Gershenson DM
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S62-72. PubMed ID: 7530680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of prognostic factors in early stage ovarian carcinoma].
    Sevelda P
    Zentralbl Gynakol; 1996; 118(6):326-9. PubMed ID: 8768008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant ovarian germ cell tumors: a single-institution experience.
    Cicin I; Eralp Y; Saip P; Ayan I; Kebudi R; Iyibozkurt C; Tuzlali S; Gorgun O; Topuz E
    Am J Clin Oncol; 2009 Apr; 32(2):191-6. PubMed ID: 19307952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Histologic classification and morphologic prognostic factors in malignant ovarian tumors].
    Horn LC; Fricke K; Krugmann J
    Zentralbl Gynakol; 1995; 117(7):335-45. PubMed ID: 7668062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of ovarian cancer with combined operative, radiologic and cytostatic therapy].
    Ullrich D; Grimm D; Rothe K; Glaser FH; Heider KM; Woraschk A; Hänsgen G; Köhler L; Schöneich V
    Zentralbl Gynakol; 1985; 107(10):628-33. PubMed ID: 3160189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy.
    Kuhn W; Pache L; Schmalfeldt B; Dettmar P; Schmitt M; Jänicke F; Graeff H
    Gynecol Oncol; 1994 Dec; 55(3 Pt 1):401-9. PubMed ID: 7835780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Results of fertility preserving operations in malignant ovarian tumors].
    Kleine W
    Zentralbl Gynakol; 1996; 118(6):317-21. PubMed ID: 8768006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.